Sanofi US News

Companies also announce submission of dupilumab supplemental BLA for uncontrolled, persistent asthma

High and durable response rate in disease without any FDA-approved therapies

* First FDA-approved follow-on mealtime insulin

Phase 3 trials will evaluate isatuximab, an anti-CD38 antibody, in combination with other cancer treatments 

First head-to-head randomized clinical trial comparing the efficacy and safety of Toujeo (insulin glargine 300 Units/mL) versus insulin degludec

Two large real-world analyses compared adults with type 2 diabetes who were switched to Toujeo (insulin glargine injection 300 Units/mL) to those switched to insulin degludec